Endpoints Capital

Great fireside chat about the trends and challenges that biotechs are facing to raise capital, with great insights from industry experts. Thanks InCorp Advisory Australia for hosting a great event. Look out for more information and webinars from the event!

A huge thank you to AusBiotech for hosting another inspiring Women in Life Sciences Luncheon. At Endpoints Capital, we are proud to support this initiative that celebrates the contribution of talented women across the #lifesciences industry. #Diversity drives #innovation and fostering connections that help shape the future of biotech. The life sciences sector employs nearly 350,000 people nationwide, with women making up 40% of the workforce. Honored to be part of this important discussion. Let’s continue championing diversity and inclusion in biotech! #WomeninScience #Leadership #WILS2025 #IWD #AccelerateAction

Funding the Future of Biotech in Australia 🚀 A huge thank you to everyone who joined us last night for an insightful discussion on biotech funding, co-hosted with InCorp Advisory Australia. Special thanks to our expert panelists for sharing their valuable insights: Sameer Kassam – Partner, InCorp Advisory Australia Rebecca McQualter – CEO, Chimeric Therapeutics Hashan De Silva, CFA – CEO, KP Rx Holly Stefl – CCO, Endpoints Capital Andrew Stewart – CEO, Endpoints Capital Key Takeaways from the Discussion: 📈 Financial Strategy – Non-dilutive capital should be a strategic part of your capital strategy to preserve equity and lower your cost of capital. 💰 Funding – Listing on the ASX can make fundraising more challenging, and securing capital always takes longer than expected, so plan ahead. 📄 Tax & Compliance – Time-stamped and documented R&D activities are essential for tax compliance. 🔬 RDTI – Implement a clear system for tracking time spent on research activities - proactive documentation is a must. Despite the challenges, Australia’s biotech sector has strong potential, and we’re excited to be part of the conversation shaping its future. Looking forward to continuing these discussions! #Biotech #Funding #RDTI #Investment #Innovation

Tomorrow join us for an InHouse event on funding the future of biotech in Australia, exploring non-dilutive capital, financial roadmaps and resilience strategies. Hear from Sameer Kassam (InCorp Advisory Australia), Andrew Stewart (Endpoints Capital), Hashan De Silva, CFA (KP Rx) and Rebecca McQualter (Chimeric Therapeutics) as they share practical advice to help your biotech business thrive, with networking and discussion at our Sydney offices from 5:00 PM to 8:00 PM. Learn more and register: https://lnkd.in/gQHMq-x2

Thank you to AusBiotech for hosting and to CSIRO for sponsoring such a great event, reminding us that the 'I' in CSIRO stands for Industry! AusBiotech events are invaluable for strengthening industry ties and fostering innovation. If you're looking for ways to extend your cash runway, bridge milestones, or de-risk your financing strategy, let’s talk.   Looking forward to the next #biocheers AusBiotech event! #lifesciences #RnDfunding #Networking #AusBioNSW

Funding the Future of Biotech in #Australia! Join Endpoints Capital, InCorp Advisory Australia, KP Rx, and Chimeric Therapeutics for an exclusive information and networking event designed for #biotech and #medtech innovators. At this event, you’ll gain essential insights into non-dilutive capital and how it can revolutionize biotech funding while navigating Australia’s unique financing landscape. Our expert panel will share strategies for: ✅ Optimizing financial roadmaps to fuel long-term growth ✅ Minimizing regulatory and tax risks to accelerate development ✅ Maximizing resilience in an evolving investment environment Hear from industry leaders: 🔹 Andrew Stewart – CEO, Endpoints Capital 🔹 Sameer Kassam – Partner, InCorp Advisory 🔹 Rebecca McQualter – CEO, Chimeric Therapeutics 🔹 Hashan De Silva, CFA – CEO, KP Rx Don't miss this opportunity to connect with #lifesciences industry leaders and explore #Funding solutions tailored to biotech success in Australia! Learn more & register here👉 https://lnkd.in/gQHMq-x2

Biologics are transforming the future of medicine, however financing innovation remains a challenge. Endpoints Capital is excited to have attended IMAPAC 3rd ANZ Biologics Festival 2025 to connect with #biotech leaders to explore non-dilutive R&D funding solutions that accelerate drug development. Whether you are developing cell & gene therapies, RNA, ADCs, or next-gen #biologics, we’re here to help extend your runway without dilution. Let’s discuss how strategic funding can de-risk your journey to the clinic and beyond. #BiotechFunding #ShareholderValue #ANZBiologics

🎉 2024: A Year of Impact, Growth, and Innovation at Endpoints Capital 🎉   As 2024 draws to a close, we're proud to reflect on a year filled with milestones, collaboration, and unwavering commitment to advancing biotech innovation. 🚀   📊 Key Highlights: 🔹 $60m in R&D funding to Australian life science innovators. Despite a challenging funding landscape, we helped biotechs, medtechs with creative, non-dilutive financing solutions to keep their breakthroughs moving forward. 🔹 Our team had the privilege to engage with the biotech community at events like AusBiotech 2024, where we showcased our commitment to accelerating drug development with smarter financing strategies. 🔹 Welcomed David Shields to the team, bringing even more expertise and energy to our mission of supporting R&D through strategic financing. 🤝 Thank You to Our Community To our clients, collaborators, and team—you’ve made this year unforgettable. Your passion for advancing science is why we do what we do. This year’s achievements wouldn’t have been possible without our exceptional team, visionary partners, and a shared belief in the power of science to change lives.   🌟 Looking Ahead As we step into 2025, we remain steadfast in our mission to be the #1 R&D finance partner for life science innovators. The road ahead is bright, and we're excited to fuel the next wave of breakthroughs with you! Wishing everyone a successful, healthy, and innovative New Year! 🧬💡 #AustralianInnovation #RDFinance #DrugDevelopment #YearInReview

🎄 As the year wraps up, we want to say a big THANK YOU to everyone in the life sciences community for an incredible 2024! ✨ 🚀 This year, we've seen amazing breakthroughs, relentless dedication, and progress that brings us closer to solving global health challenges. It’s been an honour to support biotech innovators through our non-dilutive R&D Financing solutions, helping bridge funding gaps to reach your next endpoint. 💡 Here’s to celebrating your achievements as we wish you all a joyful Holiday Season from all of us at Endpoints Capital! 🌟 #SeasonsGreetings #RnDFinance #BiotechFunding #LifeSciences

We’re delighted to welcome David Shields to the Endpoints Capital team! David joins us as a key player in advancing our mission to provide world-class R&D finance solutions for biotechs. With over 20 years of senior-level experience across front-line lending, credit risk, risk governance, and assurance—including significant roles at Westpac, NAB, Bendigo and Adelaide Bank, and ANZ—David brings unparalleled expertise to our growing team. His deep knowledge of credit risk management, risk modelling methodologies, and automated decision systems will be instrumental in driving our current and future initiatives. We couldn’t be more excited to have David on board as we work to support the next wave of biotech innovation. Please join us in giving him a warm welcome! 👏 #WelcomeToTheTeam #RDFinance #BiotechFunding #CreditRisk